SCHEMBL30896404

SCHEMBL30896404

Cc1cc(-c2cc3nc(C)n(C)c3cc2N)ccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.39
MAP4K4 O95819 2/20 0.39
CYP11B2 P19099 1/20 0.37
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
DYRK1A Q13627 4/20 0.35
PDE10A Q9Y233 2/20 0.35
CDK9 P50750 1/20 0.35
PDGFRB P09619 1/20 0.35
KIT P10721 1/20 0.35
FLT3 P36888 1/20 0.35
MTOR P42345 1/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNA4 P43681 1/20 0.35
PIK3CB P42338 1/20 0.34
NFATC1 O95644 1/20 0.34
CLK1 P49759 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31613172 0.95 KDM4E (0.44) KDM4EALDH1A1LMNAMAPTMAP4K4
SCHEMBL30896312 0.79 KDM4E (0.40) KDM4EALDH1A1LMNAMAPTCYP11B2
SCHEMBL30896396 0.78 ATAD2 (0.49) MAP4K4CCNCCDK8DYRK1APDE10A
SCHEMBL30896380 0.76 ALDH1A1 (0.40) KDM4EALDH1A1LMNAMAPTCYP11B2
SCHEMBL31613173 0.76 CDC7 (0.41) MAP4K4CCNCCDK8DYRK1AMTOR
SCHEMBL6200788 0.74 KDM4E (0.58) KDM4EALDH1A1LMNAMAPTDYRK1A
SCHEMBL30896357 0.73 CDC7 (0.41) MAP4K4CCNCCDK8DYRK1AMTOR
SCHEMBL30896395 0.73 PRKCI (0.40) MAP4K4CYP11B2CCNCCDK8PIK3CB
SCHEMBL30896383 0.71 ADORA2A (0.47) MAP4K4CCNCCDK8DYRK1APDE10A
SCHEMBL7086532 0.68 CCNC (0.43) MAP4K4CCNCCDK8DYRK1AMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612128-A1 COMPOUNDS AND THEIR USE FOR TREATMENT OF HEMOGLOBINOPATHIES Bristol-Myers Squibb Company (US) 2025-09-10 EP disclosed
CN-120129677-A Compounds and their use for the treatment of heme lesions 百时美施贵宝公司 2025-06-10 CN disclosed
WO-2024097932-A1 COMPOUNDS AND THEIR USE FOR TREATMENT OF HEMOGLOBINOPATHIES BRISTOL-MYERS SQUIBB COMPANY (US) 2024-05-10 WO disclosed